About the PTAB Life Sciences Report:  Each week we will report on recent developments at the PTAB involving life sciences patents.

Koios Pharmaceuticals LLC v. Medac Geselleschaft Fuer Klinische Spezial Praparate MBH

PTAB Petition:  IPR2016-01370; filed July 20, 2016

Patent at Issue:  U.S. Patent No. 8,664,231 ("Concentrated methotrexate solutions," issued March 4, 2014) claims a method for the treatment of inflammatory autoimmune diseases comprising subcutaneously administering a methotrexate in a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml.

Petitioner Koios Pharmaceuticals LLC is challenging the '231 patent on six grounds as being anticipated under 35 U.S.C. § 102(b) (grounds 1 and 4) or obviousness under 35 U.S.C. § 103(a) (grounds 2, 3, 5, and 6).  View the petition here.

Related Matters:  According to the petition, the '231 patent was involved in litigation in the District of New Jersey, captioned Medac Pharma Inc. v. Antares Pharma, Inc., 1:14-cv-1498; and in IPR2014-01091 (Antares Pharma, Inc. v. Medac Pharma Inc.; Petitioners Antares Pharm, Inc., Leo Pharma A/S, and Leo Pharma Inc.; filed on 07/01/2014; instituted on 01/06/2015; and terminated 04/30/2015 through settlement). The petition also indicates that the '231 patent is involved in IPR2016-00649 (Petitioner Frontier Therapeutics, LLC; filed on 02/22/2016; pending).

Par Pharmaceutical, Inc. v. Novartis AG

PTAB Petition:  IPR2016-01479; filed July 22, 2016

Patent at Issue:  U.S. Patent No. 9,006,224 ("Neuroendocrine tumor treatment," issued April 14, 2015) claims a device for collecting and assaying a sample of biological fluid.

Petitioner Par Pharmaceutical, Inc. is challenging the '224 patent on four grounds as being obviousness under 35 U.S.C. § 103(a) (grounds 1-4).  View the petition here.

Related Matters:  According to the petition, related matters include litigations in the District of Delaware, captioned Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:14-cv-1289-RGA; Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:14-cv-1494-RGA; Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:15-cv-78-RGA; Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:15-cv-475-RGA; and Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:15-cv-1050-RGA; and in IPR2016-1461 (Roxane Labs., Inc. v. Novartis AG).  The petition also indicates that related matters include IPR2016-00084, -01023, -01059, -01102, and -01103 (inter partes review of U.S. Patent No. 5,665,772).

Alere Inc. v. Rembrandt Diagnostics, LP

PTAB Petition:  IPR2016-01498; filed July 27, 2016

Patent at Issue:  U.S. Patent No. 8,623,291 ("Multiple analyte assay device," issued January 7, 2014) claims a device for assaying a fluid for the presence or absence of different analytes and a method for detecting a multiplicity of analytes using such a device.

Petitioner Alere Inc. is challenging the '291 patent on nine grounds as being obviousness under 35 U.S.C. § 103(a) (grounds 1-9).  View the petition here.

Related Matters:  According to the petition, the '291 patent is involved in litigation in the Southern District of California, captioned Rembrandt Diagnostics, LP v. Alere Inc., et al., No. 3:16-cv-698-CAB-NLS.

Alere Inc. v. Rembrandt Diagnostics, LP

PTAB Petition:  IPR2016-01502; filed July 27, 2016

Patent at Issue:  U.S. Patent No. 6,548,019 ("Device and methods for single step collection and assaying of biological fluids," issued April 15, 2003) claims a device for collecting and assaying a sample of biological fluid.

Petitioner Alere Inc. is challenging the '019 patent on thirteen grounds as being anticipated under 35 U.S.C. § 102(b) (grounds 1 and 5) or obviousness under 35 U.S.C. § 103(a) (grounds 2-4 and 6-13).  View the petition here.

Related Matters:  According to the petition, the '019 patent is involved in litigation in the Southern District of California, captioned Rembrandt Diagnostics, LP v. Alere, Inc., et al., No. 3:16-cv-698-CAB-NLS.